Oruka Therapeutics, Inc.

Developing long-acting antibodies targeting IL-23 and IL-17 pathways for psoriasis and related inflammatory diseases.

Back to company catalog

Immunology & inflammation · Long-acting monoclonal antibodies · Clinical (Phase 2)

Compare report options